Sees 2024 adjusted operating earnings $100M-$125M vs. $80M-$110M prior. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SUPN: SUPN Earnings this Week: How Will it Perform? Supernus resubmits SPN-830 NDA after addressing complete response letter Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 Disclaimer & DisclosureReport an Issue
